Postpartum Depression Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The postpartum depression market size has grown exponentially in recent years. It will grow from $12.15 billion in 2024 to $16.09 billion in 2025 at a compound annual growth rate (CAGR) of 32.4%. The growth in the historic period can be attributed to maternal mental health awareness, research advancements, public health initiatives, increased screenings.

The postpartum depression market size is expected to see exponential growth in the next few years. It will grow to $49.4 billion in 2029 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to telehealth services, pharmacological advancements, maternal mental health legislation, mental health workforce expansion. Major trends in the forecast period include integrated care models, peer support programs, perinatal mental health apps, mental health screening tools.

An increase in postpartum depression cases is expected to drive the growth of the postpartum depression market. Postpartum depression refers to excessive worry and emotional distress that occurs after childbirth, often accompanied by physical symptoms. It is common for postpartum depression to coexist with postnatal depression and anxiety, with symptoms potentially starting at any point during the first year after birth. Treatment options for postpartum depression include psychotherapy, also known as talk therapy or mental health counseling, medications, or a combination of both, which contributes to the market's growth. For example, a survey of 1.1 million mothers conducted by the University of Virginia School of Medicine (UVA SoM) in February 2022, found that first-time mothers, those under 25, and mothers of twins were most at risk for postpartum depression. Among age groups, women aged 18-24 had the highest self-reported rate of postpartum depression symptoms at 10%. Mothers of twins had a higher rate of symptoms (11.3%) compared to those with single children (8.3%). As such, the rising incidence of postpartum depression will drive the growth of the postpartum depression market.

The growing number of childbirths is expected to accelerate the growth of the postpartum depression market. Childbirth is the process in which a baby is born from the mother's uterus, usually through the vaginal canal. The increase in childbirths contributes to the postpartum depression market, as this condition is a common mental health issue affecting women following delivery. Postpartum depression can lead to various symptoms, such as sadness, anxiety, fatigue, and difficulty bonding with the baby. For instance, a report published by the Centers for Disease Control and Prevention (CDC) in January 2023 indicated a 1% rise in registered births in the United States, reaching a total of 3,664,292 births compared to the previous year. Therefore, the rising number of childbirths is driving the expansion of the postpartum depression market.

Companies active in the postpartum depression market are focusing on innovation to maintain their market presence. The need for faster-acting therapies and innovative care delivery methods for postpartum depression has arisen due to the limited treatment options available. For example, in February 2023, Biogen Inc., a U.S.-based biotechnology company, and Sage Therapeutics Inc., a U.S.-based biopharmaceutical company, announced the acceptance of a new drug application (NDA) by the United States Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an experimental medication being investigated as a 14-day, once-daily, fast-acting oral therapy for individuals with MDD and PPD. As a neuroactive steroid, zuranolone functions as a positive allosteric modulator of GABA-A receptors, offering a unique mechanism of action. It is designed to rapidly reset dysregulated neural networks to aid in restoring brain function and, in turn, influence the brain networks responsible for mood, arousal, behavior, and cognition.

In December 2022, Biogen Inc. and Sage Therapeutics Inc. joined forces for an undisclosed amount, aimed at the development and commercialization of drugs for major depressive disorder (MDD), postpartum depression (PPD), as well as other mental disorders, essential tremor, and various neurological conditions. Sage Therapeutics Inc. specializes in the development of therapies for neurological conditions such as depression, PPD, neurology, and neuropsychiatric disorders. This collaboration enhances the prospects for advancing treatments in the field of mental health and neurology.

Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

North America was the largest region in the postpartum depression market in 2024. The regions covered in postpartum depression report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the postpartum depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The postpartum depression market consists of revenues earned by entities by providing services such as medications, psychotherapy (cognitive behavioral therapy) and support group participation. The market value includes the value of related goods sold by the service provider or included within the service offering. The postpartum depression market also includes the sales of medications such as Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), Bupropion and Tricyclic antidepressants (TCAs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Postpartum depression (PPD) is a mood disorder that affects some women after giving birth and often goes undiagnosed for extended periods. It is characterized by feelings of sadness, hopelessness, and a loss of interest or pleasure in activities once enjoyed.

The main types of postpartum depression include postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum panic disorder, postpartum post-traumatic stress disorder, postpartum psychosis, and others. Postpartum blues is a common but self-limiting condition that occurs shortly after childbirth, featuring symptoms such as mood swings, irritability, and tearfulness. Treatment for postpartum depression involves various approaches, including psychotherapy, medication, supplements, and other therapeutic interventions. These treatments can be administered in different ways, such as orally, through injections, and more. Postpartum depression remedies are available through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a range of end-users, including hospitals, specialty clinics, home-care settings, and others.

The postpartum depression market research report is one of a series of new reports that provides postpartum depression market statistics, including postpartum depression industry global market size, regional shares, competitors with a postpartum depression market share, detailed postpartum depression market segments, market trends and opportunities and any further data you may need to thrive in the postpartum depression industry. This postpartum depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.